166 related articles for article (PubMed ID: 12637154)
1. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.
Williams EE; Trout LJ; Gallo RM; Pitfield SE; Bryant I; Penington DJ; Riese DJ
Cancer Lett; 2003 Mar; 192(1):67-74. PubMed ID: 12637154
[TBL] [Abstract][Full Text] [Related]
2. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.
Pitfield SE; Bryant I; Penington DJ; Park G; Riese DJ
Oncol Res; 2006; 16(4):179-93. PubMed ID: 17120616
[TBL] [Abstract][Full Text] [Related]
5. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.
Gallo RM; Bryant I; Fry R; Williams EE; Riese DJ
Biochem Biophys Res Commun; 2006 Oct; 349(1):372-82. PubMed ID: 16934755
[TBL] [Abstract][Full Text] [Related]
7. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.
Penington DJ; Bryant I; Riese DJ
Cell Growth Differ; 2002 Jun; 13(6):247-56. PubMed ID: 12114214
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
9. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
10. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
11. Desensitization by different strategies of epidermal growth factor receptor and ErbB4.
Yamamoto H; Higa-Nakamine S; Noguchi N; Maeda N; Kondo Y; Toku S; Kukita I; Sugahara K
J Pharmacol Sci; 2014; 124(3):287-93. PubMed ID: 24553453
[TBL] [Abstract][Full Text] [Related]
12. Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.
Gallo RM; Bryant IN; Mill CP; Kaverman S; Riese DJ
J Cancer Res Ther Oncol; 2013 Aug; 1(1):10. PubMed ID: 24791013
[TBL] [Abstract][Full Text] [Related]
13. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
14. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
15. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
17. EGFR signaling in breast cancer: bad to the bone.
Foley J; Nickerson NK; Nam S; Allen KT; Gilmore JL; Nephew KP; Riese DJ
Semin Cell Dev Biol; 2010 Dec; 21(9):951-60. PubMed ID: 20813200
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
19. A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities.
Vidal GA; Clark DE; Marrero L; Jones FE
Oncogene; 2007 Jan; 26(3):462-6. PubMed ID: 16832345
[TBL] [Abstract][Full Text] [Related]
20. Role of ErbB4 in breast cancer.
Sundvall M; Iljin K; Kilpinen S; Sara H; Kallioniemi OP; Elenius K
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):259-68. PubMed ID: 18454307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
